Over the past 12 months, 10 insiders at Immunovant, Inc. filed 44 open-market SEC Form 4 transactions on IMVT: 1 purchase worth $350.0M and 43 sales worth $12.4M. Insiders have been net sellers over this period. The most recent filing was on Jul 24, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 26 | Atul PandeDirector | SELL | 1.5K | $39.80 | $60K |
| Jul 23, 26 | Tiago GiraoChief Financial Officer | SELL | 6.8K | $38.69 | $263K |
| Jul 23, 26 | Jay S StoutChief Technology Officer | SELL | 2.9K | $38.69 | $111K |
| Jul 8, 26 | Melanie GloriaChief Operating Officer | SELL | 1.9K | $39.99 | $76K |
| Jul 8, 26 | Jay S StoutChief Technology Officer | SELL | 1.9K | $39.99 | $75K |
| Jul 8, 26 | Tuyl Christopher VanChief Legal Officer | SELL | 1.1K | $39.99 | $45K |
| Jul 2, 26 | Eric VenkerChief Executive Officer | SELL | 3.1K | $38.48 | $119K |
| Jun 26, 26 | Tiago GiraoChief Financial Officer | SELL | 10.0K | $38.46 | $385K |
| Jun 26, 26 | Melanie GloriaChief Operating Officer | SELL | 14.7K | $38.95 | $563K |
| Jun 26, 26 | Atul Pande | SELL | 1.5K | $38.01 | $57K |
| Jun 15, 26 | Atul Pande | SELL | 1.5K | $34.02 | $51K |
| May 28, 26 | Andrew J. Fromkin | SELL | 210.5K | $33.56 | $7.1M |
| May 20, 26 | Melanie GloriaChief Operating Officer | SELL | 1.7K | $32.95 | $56K |
| Apr 23, 26 | Tiago GiraoChief Financial Officer | SELL | 25.8K | $29.62 | $763K |
| Apr 8, 26 | Melanie GloriaChief Operating Officer | SELL | 8.7K | $24.83 | $217K |
| Mar 18, 26 | Tuyl Christopher VanChief Legal Officer | SELL | 2.9K | $24.97 | $72K |
| Feb 25, 26 | Melanie GloriaChief Operating Officer | SELL | 1.4K | $28.90 | $39K |
| Jan 21, 26 | Jay S StoutChief Technology Officer | SELL | 2.0K | $26.03 | $51K |
| Jan 7, 26 | Jay S StoutChief Technology Officer | SELL | 1.1K | $26.92 | $30K |
| Dec 18, 25 | Tuyl Christopher VanChief Legal Officer | SELL | 8.5K | $27.38 | $228K |
| Dec 12, 25 | Roivant Sciences Ltd.Director,TenPercentOwner | BUY | 16.67M | $21.00 | $350.0M |
| Dec 1, 25 | Andrew J. FromkinDirector | SELL | 19.4K | $23.95 | $448K |
| Dec 1, 25 | Douglas J. HughesDirector | SELL | 13.1K | $23.96 | $303K |
| Nov 20, 25 | Melanie GloriaChief Operating Officer | SELL | 10.3K | $23.97 | $241K |
| Oct 22, 25 | Michael GeffnerChief Medical Officer | SELL | 2.6K | $19.03 | $49K |
| Oct 22, 25 | Jay S StoutChief Technology Officer | SELL | 2.5K | $19.03 | $48K |
| Oct 8, 25 | Michael GeffnerChief Medical Officer | SELL | 1.3K | $16.30 | $21K |
| Oct 8, 25 | Jay S StoutChief Technology Officer | SELL | 1.6K | $16.30 | $26K |
| Jul 23, 25 | Michael GeffnerChief Medical Officer | SELL | 2.4K | $18.15 | $43K |
| Jul 23, 25 | Jay S StoutChief Technology Officer | SELL | 2.8K | $18.15 | $51K |
| Jul 9, 25 | Michael GeffnerChief Medical Officer | SELL | 1.2K | $17.24 | $20K |
| Jul 9, 25 | Jay S StoutChief Technology Officer | SELL | 1.5K | $17.24 | $26K |
| Apr 23, 25 | Michael GeffnerChief Medical Officer | SELL | 2.3K | $14.79 | $35K |
| Apr 23, 25 | Jay S StoutChief Technology Officer | SELL | 1.9K | $14.79 | $28K |
| Apr 16, 25 | Eva Renee BarnettChief Financial Officer | SELL | 3.0K | $14.89 | $45K |
| Apr 16, 25 | Peter SalzmannChief Executive Officer | SELL | 8.3K | $14.89 | $124K |
| Apr 9, 25 | Eva Renee BarnettChief Financial Officer | SELL | 7.0K | $12.99 | $91K |
| Apr 9, 25 | Michael GeffnerChief Medical Officer | SELL | 6.2K | $12.99 | $80K |
| Apr 9, 25 | Peter SalzmannChief Executive Officer | SELL | 28.1K | $12.99 | $365K |
| Apr 9, 25 | Jay S StoutChief Technology Officer | SELL | 5.0K | $12.99 | $65K |
| Mar 7, 25 | Andrew J. FromkinDirector | SELL | 6.6K | $19.96 | $129K |
| Feb 19, 25 | Eva Renee BarnettChief Financial Officer | SELL | 2.8K | $20.86 | $59K |
| Feb 19, 25 | William L. MaciasChief Medical Officer | SELL | 2.1K | $20.86 | $43K |
| Feb 19, 25 | Peter SalzmannChief Executive Officer | SELL | 15.4K | $20.86 | $322K |
| Jan 22, 25 | Michael GeffnerChief Medical Officer | SELL | 2.7K | $23.59 | $63K |
| Jan 22, 25 | Jay S StoutChief Technology Officer | SELL | 2.2K | $23.59 | $52K |
| Jan 15, 25 | Eva Renee BarnettChief Financial Officer | SELL | 2.2K | $24.19 | $52K |
| Jan 15, 25 | William L. MaciasChief Medical Officer | SELL | 1.9K | $24.19 | $45K |
| Jan 15, 25 | Peter SalzmannChief Executive Officer | SELL | 8.4K | $24.19 | $199K |
| Jan 13, 25 | Roivant Sciences Ltd.Director,TenPercentOwner | BUY | 16.85M | $20.00 | $336.9M |
Over the past 12 months, insiders at Immunovant, Inc. filed 1 open-market purchase worth $350.0M and 43 sales worth $12.4M on IMVT, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 24, 26.
The largest recent open-market IMVT insider purchase in our data was $350.0M by Roivant Sciences Ltd., Director,TenPercentOwner, filed on Dec 12, 25.
10 different insiders at Immunovant, Inc. filed open-market SEC Form 4 transactions on IMVT over the last 12 months.
InsiderTape plots every IMVT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Immunovant, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →